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Abstract: This paper discusses the current data concerning the results of major clinical trials using bone marrow-derived and
peripheral blood-derived stem/progenitor cells in treatment of patients with acute myocardial infarction (AMI) and depressed
left ventricular ejection fraction. In all major trials (TOPCARE-AMI, BOOST), the primary outcome measure was increase in
left ventricular systolic function (LVEF) and left ventricle remodeling. The most consistent finding is the significant increase
in LVEF. Some trials suggest also reduction of left ventricular remodeling. Although the absolute LVEF increase is small
(6-9%), it may substantially contribute to the improvement of global LV contractility. None of the studies in AMI patients
treated with intracoronary infusion of progenitor cells revealed excess risk of arrythmia, restenosis or other adverse effects
attributable to the therapy. The exact mechanism of improved myocardial contractile function remains unknown, however,
there are several possible explanations: therapeutic angiogenesis improving the blood supply to the infarct border zone,
paracrine modulation of myocardial fibrosis and remodeling (e.g. inhibition of myocyte apoptosis) and transdifferentiation of
stem/progenitor cells into functional cardiomyocytes. No study showed the superiority of the particular subpopulation of
autologous progenitor cells in terms of left ventricular function improvement in AMI. In fact, most of the clinical trials used
the whole population of mononuclear bone marrow-derived progenitor cells, peripheral blood derived progenitor cells
(endothelial progenitors). 
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Introduction
In spite of the widespread availability of percutaneous
coronary intervention (PCI) and pharmacological reper-
fusion therapy in patients with acute myocardial infarc-
tion (AMI), the long-term outcomes in substantial group
of patients is unfavorable due to large area of myocardial
necrosis with subsequent contractile dysfunction lead-
ing to development of ischemic cardiomyopathy and
heart failure. It was shown in animal models that bone
marrow-derived and peripheral blood-derived adult pro-
genitor cells have the potential to improve myocardial
recovery in ST-segment elevation myocardial infarction
(STEMI) [2, 4, 8]. Moreover, clinical trials were carried
out to test the hypothesis that bone marrow-derived
progenitor cells may improve the myocardial recovery
after AMI.
Mechanisms of myocardial repair
The exact mechanism of improved myocardial contrac-
tile function remains unknown. The following phenome-
na can contribute to myocardial salvage after therapy
with progenitor cells [2, 4, 8]: (1) therapeutic angiogen-
esis improving the blood supply to the infarct border
zone (2) paracrine modulation of myocardial fibrosis
and remodeling (e.g. inhibition of myocyte apoptosis)
and (3) transdifferentiation of progenitor cells into func-
tional cardiomyocytes (the most questionable pathway).
Types of adult progenitor cells used in clinical
trials
So far no study has shown the superiority of any particu-
lar subpopulation of autologous progenitor cells in terms
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of left ventricular function improvement in AMI. In fact,
most of the clinical trials used the whole population of
mononuclear bone marrow-derived progenitor cells, pe-
ripheral blood derived progenitor cells (endothelial pro-
genitors). Skeletal muscle myoblasts used in chronic
heart failure are not feasible in STEMI patients because
the need of expansion in cultures lasting days or weeks
[2, 9]. TOPCARE-AMI investigators reported greater
LVEF improvement associated with good migratory
capacity of progenitor cells evidenced as the chemotaxis
to stromal cell-derived factor (SDF-1) suggesting that
cells positive for SDF-1 receptor CXCR4 may be im-
portant in cardiac salvage [1]. This issue will be ad-
dressed in REGENT multicenter trial which compares
two population of cells - unselected bone marrow-
derived mononuclear cells with sorted CD34/CXCR4+
cells - in patients with AMI and low LVEF. 
Outcome measures
In all completed trials, the primary outcome measures
are the parameters of left ventricular systolic function
(LVEF) and remodeling - changes in left ventricular
end-diastolic volume (LVEDV), left ventricular end-
systolic volume (LVESV), and left ventricular end-sys-
tolic diameter LVESD) measured by the most sensitive
diagnostic method - cardiac magnetic resonance im-
aging (MRI), as well as contrast ventriculography and
Table 1. Major clinical trials involving intracoronary infusion of bone marrow-derived or peripheral blood-derived stem cells in acute
myocardial infarction 
Study Type/source of cells N Follow-up Outcome measures
Strauer et al. [7] Intracoronary BMC 10 3 months
↔ LVEF (LV angio) 
↓ LVESD
↑ myocardial perfusion
↑ regional contractility
TOPCARE-AMI [5] Intracoronary BMC or CPC 59 1 year
↑ LVEF (MRI)
↔ LVEDV 
↓LVESV
↑ viability 
↑ flow reserve 
BOOST Trial [9] Intracoronary BMC 60 6 months ↑ LVEF (MRI)
↔ LVESV, LVEDV
Fernandez-Aviles et al. [3] Intracoronary BMC 20 6 months
↑ LVEF (MRI)
↓LVESV
↔ LVEDV
BMC - bone marrow-derived cells; CPC - circulating progenitor cells; LVEF - left ventricular ejection fraction, LVEDV - left ventricular
end-diastolic volume, LVESV - left ventricular end-systolic volume, LVESD - left ventricular end-systolic diameter, MRI - magnetic
resonance imaging 
Table 2. Safety of intracoronary infusion of progenitor cells in acute myocardial infarction in major clinical trials.
Study Type of adverse event N Relation to therapy Outcome 
Strauer et al. [7] (-) 10 (-) (-)
TOPCARE-AMI [5]
Thrombotic occlusion of IRA during second
angiography prior to cell infusion 1 Instrumentation-related Recovered
AMI (stent thrombosis in vessel other than
IRA in index AMI) 1 None Recovered
Fatal AMI (subacute stent thrombosis in
IRA) 1 Unlikely Died
BOOST Trial [9]
NSTEMI (vessel other than IRA in index
AMI) 1 None Recovered
Hospitalization due to worsening of heart
failure 1 None Recovered
VT/VF inducible in EPS 2 None Recovered
Fernandez-Aviles et al. [3] TIA 1 None Recovered
IRA - infarct-related artery; TIA - transient ischemic attack, VT - ventricular tachycardia; VF - ventricular fibrillation, AMI - acute myocardial
infarction; NSTEMI - non-ST-segment elevation acute myocardial infarction.
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echocardiography. Some studies employed MRI-as-
sisted functional tests (coronary flow reserve) and as-
sessment of infarct size and mass (TOPCARE-AMI) [5,
9]. The most consistent finding is the increase in LVEF
(Table 1). Some trials suggest also reduction of left
ventricular remodeling (TOPCARE-AMI). Although
the absolute LVEF increase is small (6-9%), it may
substantially contribute to the improvement of global
LV contractility. Also longer follow-up seems necessary
since as shown in TOPCARE-AMI there is further im-
provement in LVEF as revealed by MRI performed after
4 months and after 1 year [5].
Safety
As in every other experimental therapy, the safety issues
remain fundamental. Previous data concerning the
proarrythmogenic properties of skeletal muscle
myoblasts [6] warranted ECG Holter monitoring in
every patient receiving progenitor cells. Some trials also
used invasive electrophysiological study [9]. So far none
of the studies in AMI patients treated with intracoronary
infusion of progenitor cells revealed excess risk of ar-
rythmia, restenosis or other adverse effects attributable
to the therapy (Table 2). The overall rate of cardiovas-
cular adverse events did not differ between the patients
treated routinely and subjects receiving the progenitor
cell infusion [3, 5, 9].
Which patients benefit most?
Most of the trials involved small groups of patients, so
the validity of sub-group analyses is questionable. It
seems that the benefits of cell therapy are uniformly
distributed regardless of sex, age, renal function,
presence of hypertension, hyperlipidemia, diabetes, ex-
tent of coronary atherosclerosis and time to revascular-
ization. No associations were also found between the
cell type and number and LVEF increase [1, 5, 9].
However, baseline LVEF value was an independent
predictor of LVEF improvement, suggesting that pa-
tients with the most substantial myocardial damage have
the most significant improvement after cell therapy [5].
The efficiency of the progenitor cell therapy will be
assessed in ongoing large clinical trial REPAIR-AMI
(200 patients). Based on the results of randomized clini-
cal trials, the intracoronary infusion of progenitor cells
seems to be a safe and effective adjunctive method of
treatment in patients with AMI who after successful
coronary reperfusion develop significant left ventricular
dysfunction, however, the double-blind placebo-con-
trolled trial is necessary to confirm the findings.
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